Cargando…
Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice
BACKGROUND: Treatments for pancreatic ductal adenocarcinoma are poorly effective, at least partly due to the tumor’s immune-suppressive stromal compartment. New evidence of positive effects on immune responses in the tumor microenvironment (TME), compelled us to test the combination of gemcitabine (...
Autores principales: | Selvanesan, Benson Chellakkan, Meena, Kiran, Beck, Amanda, Meheus, Lydie, Lara, Olaya, Rooman, Ilse, Gravekamp, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646363/ https://www.ncbi.nlm.nih.gov/pubmed/33154149 http://dx.doi.org/10.1136/jitc-2020-001250 |
Ejemplares similares
-
32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect
por: Chandra, Dinesh, et al.
Publicado: (2017) -
Tumorous expression of NAC1 restrains antitumor immunity through the LDHA-mediated immune evasion
por: Ren, Yijie, et al.
Publicado: (2022) -
Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer
por: Travelli, Cristina, et al.
Publicado: (2023) -
On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients
por: Verbaanderd, Ciska, et al.
Publicado: (2020) -
DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells
por: Cueto, Francisco J, et al.
Publicado: (2021)